Skip to main content
Faes Farma S.A. logo

Faes Farma S.A. — Investor Relations & Filings

Ticker · FAE ISIN · ES0134950F36 LEI · 959800FXZQY7U3P1G969 MC Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2021-02-26 Remuneration Information
Country ES Spain
Listing MC FAE

About Faes Farma S.A.

https://faesfarma.com/en/

Faes Farma S.A. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products, healthcare solutions, and animal nutrition products. The company's pharmaceutical division develops treatments for conditions in therapeutic areas including allergy, gastroenterology, and immunology, with key proprietary molecules such as Bilastine, a leading antihistamine, and Calcifediol for Vitamin D deficiency. The animal nutrition business provides nutritional solutions and supplements for sustainable animal production. A core focus of the company is its investment in R&D to develop novel molecules and health solutions for its global markets.

Recent filings

Filing Released Lang Actions
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del Ejercicio 2020
Remuneration Information Classification · 99% confidence The document text extensively details the 'POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD' (Remuneration Policy of the Company), specifically focusing on the compensation structure, fixed and variable components, long-term incentives, and termination clauses for directors and executive officers (Consejero ejecutivo). This content directly aligns with the disclosure requirements for executive and director compensation, which is the primary focus of a Remuneration Information document, often filed under regulations like the Spanish CNMV's requirements or equivalent to a US DEF 14A proxy statement section on compensation. The reference to the fiscal year 2020 and the detailed breakdown of fixed pay (€70k for directors, €919k fixed for the President) and variable pay structure confirms this is a detailed report on remuneration, not just a brief announcement.
2021-02-26 Spanish
Corporate Governance Report - Faes Farma S.A.
Remuneration Information Classification · 99% confidence The document text is highly detailed, focusing exclusively on the 'Política de Remuneraciones de la Sociedad' (Remuneration Policy of the Company) for the current fiscal year (2020), detailing fixed and variable compensation, long-term incentives, and severance clauses for directors and executives. This content directly corresponds to the disclosure requirements for executive and director compensation. Among the provided codes, 'DEF 14A' is defined as 'Remuneration Information' (Report detailing compensation for top executives and directors). Although the document is in Spanish and might be part of a larger filing (like an Annual Report or Proxy Statement), its specific content focus mandates classification as Remuneration Information.
2021-02-26 Spanish
Annual Report 2020
Annual Report Classification · 100% confidence The document contains the full financial statements (Balance Sheet, Profit and Loss, Statement of Changes in Equity, Cash Flow Statement) and detailed notes (Memoria) for Faes Farma, S.A. for the fiscal year ending December 31, 2020. It is a comprehensive annual financial report, not an announcement or a summary, and therefore qualifies as an Annual Report (10-K equivalent in this context). FY 2020
2021-02-26 Spanish
Annual Report 2020
Annual Report Classification · 100% confidence The document contains comprehensive consolidated financial statements for Faes Farma, S.A. for the fiscal year ending December 31, 2020. It includes a balance sheet, income statement, statement of comprehensive income, and statements of changes in equity. As this is a full annual financial report covering the entire fiscal year, it is classified as an Annual Report (10-K). FY 2020
2021-02-26 Spanish
Annual Report (ESEF) 2020
Annual Report (ESEF) Classification · 100% confidence FY 2020
2021-02-26 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 99% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMR) AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form explicitly details transactions (share volume, price, date) conducted by a director (Mariano Ucar Angulo, President) of the issuer (FAES FARMA, S.A.). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2021-01-27 Spanish

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.